1 day Ago By ABMN Staff
Evotec SE ( NASDAQ:EVO – Get Free Report ) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 191,400 shares, a drop of 8.6% from the August 15th total of 209,500 shares.
Based on an average trading volume of 90,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.
1% of the company’s shares are sold short. Evotec Stock Performance NASDAQ:EVO opened at $3.64 on Thursday.
Evotec has a 52 week low of $2.85 and a 52 week high of $12.00.
The stock’s fifty day moving average is $3.88 and its two-hundred day moving average is $5.20.
The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.
83. Institutional Investors Weigh In On Evotec A number of institutional investors have recently modified their holdings of the company. Novo Holdings A S purchased a new stake in shares of Evotec during the second quarter worth approximately $71,183,000.
Mubadala Investment Co PJSC acquired a new stake in Evotec in the fourth quarter valued at $53,931,000. DCF Advisers LLC boosted its position in shares of Evotec by 140.5% during the 2nd quarter.
DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after acquiring an additional 67,156 shares in the last quarter. Optiver Holding B.V.
increased its holdings in shares of Evotec by 643.1% in the 4th quarter. Optiver Holding B.
V. now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares during the last quarter. Finally, Cetera Advisors LLC acquired a new position in Evotec in the first quarter valued at $188,000.
5.81% of the stock is owned by institutional investors and hedge funds. Wall Street Analyst Weigh In View Our Latest Report on Evotec Evotec Company Profile ( Get Free Report ) Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. Featured Articles Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter .
.
